
Argenx’s VYVGART Hytrulo Receives FDA Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the well-being of individuals with severe autoimmune conditions, has announced today that the U.S. Food and Drug…













